No drug has shown to improve all-cause mortality in patients with chronic obstructive pulmonary disease — a fact that led the FDA to pen a warning letter to AstraZeneca for its advertising of its COPD drug Breztri Aerosphere.
Read the full post on Becker's Hospital Review - Healthcare News
